Literature DB >> 29394359

Ribitol-phosphate-a newly identified posttranslational glycosylation unit in mammals: structure, modification enzymes and relationship to human diseases.

Motoi Kanagawa1, Tatsushi Toda1,2.   

Abstract

GLYCOSYLATION IS A CRUCIAL POSTTRANSLATIONAL MODIFICATION THAT IS INVOLVED IN NUMEROUS BIOLOGICAL EVENTS. THEREFORE, ABNORMAL GLYCOSYLATION CAN IMPAIR THE FUNCTIONS OF GLYCOPROTEINS OR GLYCOLIPIDS AND IS OCCASIONALLY ASSOCIATED WITH CELL DYSFUNCTION AND HUMAN DISEASES. FOR EXAMPLE, ABERRANT GLYCOSYLATION OF DYSTROGLYCAN (DG), A CELLULAR RECEPTOR FOR MATRIX AND SYNAPTIC PROTEINS, IS ASSOCIATED WITH MUSCULAR DYSTROPHY AND LISSENCEPHALY. DG SUGAR CHAINS ARE REQUIRED FOR HIGH-AFFINITY BINDING TO LIGAND PROTEINS, AND THUS DISRUPTION OF DG-LIGAND LINKAGES UNDERLIES DISEASE CONDITIONS. ALTHOUGH THEIR BIOLOGICAL SIGNIFICANCE IS WELL RECOGNIZED, THE SUGAR-CHAIN STRUCTURE OF DG AND ITS MODIFICATION ENZYMES HAVE LONG REMAINED INCOMPLETELY ELUCIDATED. HOWEVER, RECENT SEMINAL STUDIES HAVE FINALLY REVEALED A HIGHLY REGULATED MECHANISM FOR DG GLYCOSYLATION AND HAVE DISCOVERED A POSTTRANSLATIONAL UNIT, RIBITOL-PHOSPHATE, THAT WAS NOT PREVIOUSLY KNOWN TO BE USED IN MAMMALS. THIS REVIEW ARTICLE INTRODUCES THE STRUCTURE, MODIFICATION ENZYMES AND FUNCTIONS OF THE SUGAR CHAINS OF DG, AND THEN DISCUSSES THEIR RELATIONSHIP TO HUMAN DISEASES AND THERAPEUTIC STRATEGIES: .

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29394359     DOI: 10.1093/jb/mvy020

Source DB:  PubMed          Journal:  J Biochem        ISSN: 0021-924X            Impact factor:   3.387


  9 in total

1.  CDP-glycerol inhibits the synthesis of the functional O-mannosyl glycan of α-dystroglycan.

Authors:  Rieko Imae; Hiroshi Manya; Hiroki Tsumoto; Kenji Osumi; Tomohiro Tanaka; Mamoru Mizuno; Motoi Kanagawa; Kazuhiro Kobayashi; Tatsushi Toda; Tamao Endo
Journal:  J Biol Chem       Date:  2018-06-08       Impact factor: 5.157

2.  O-Glycologue: A Formal-Language-Based Generator of O-Glycosylation Networks.

Authors:  Andrew G McDonald; Gavin P Davey
Journal:  Methods Mol Biol       Date:  2022

3.  HNK-1 sulfotransferase modulates α-dystroglycan glycosylation by 3-O-sulfation of glucuronic acid on matriglycan.

Authors:  M Osman Sheikh; David Venzke; Mary E Anderson; Takako Yoshida-Moriguchi; John N Glushka; Alison V Nairn; Melina Galizzi; Kelley W Moremen; Kevin P Campbell; Lance Wells
Journal:  Glycobiology       Date:  2020-09-28       Impact factor: 4.313

Review 4.  Fukutin-Related Protein: From Pathology to Treatments.

Authors:  Carolina Ortiz-Cordero; Karim Azzag; Rita C R Perlingeiro
Journal:  Trends Cell Biol       Date:  2020-12-01       Impact factor: 20.808

Review 5.  Myo-Glyco disease Biology: Genetic Myopathies Caused by Abnormal Glycan Synthesis and Degradation.

Authors:  Motoi Kanagawa
Journal:  J Neuromuscul Dis       Date:  2019

Review 6.  Dystroglycanopathy: From Elucidation of Molecular and Pathological Mechanisms to Development of Treatment Methods.

Authors:  Motoi Kanagawa
Journal:  Int J Mol Sci       Date:  2021-12-06       Impact factor: 5.923

7.  CDP-ribitol prodrug treatment ameliorates ISPD-deficient muscular dystrophy mouse model.

Authors:  Hideki Tokuoka; Rieko Imae; Hitomi Nakashima; Hiroshi Manya; Chiaki Masuda; Shunsuke Hoshino; Kazuhiro Kobayashi; Dirk J Lefeber; Riki Matsumoto; Takashi Okada; Tamao Endo; Motoi Kanagawa; Tatsushi Toda
Journal:  Nat Commun       Date:  2022-04-14       Impact factor: 17.694

8.  Facile triflic acid-catalyzed α-1,2-cis-thio glycosylations: scope and application to the synthesis of S-linked oligosaccharides, glycolipids, sublancin glycopeptides, and TN/TF antigens.

Authors:  Sanyong Zhu; Ganesh Samala; Eric T Sletten; Jennifer L Stockdill; Hien M Nguyen
Journal:  Chem Sci       Date:  2019-10-01       Impact factor: 9.825

9.  High degree of conservation of the enzymes synthesizing the laminin-binding glycoepitope of α-dystroglycan.

Authors:  Maria Giulia Bigotti; Andrea Brancaccio
Journal:  Open Biol       Date:  2021-09-29       Impact factor: 6.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.